However, this difference may reflect tumor type heterogeneity rather than differential drug effects, because all anti-CTLA-4 therapies were performed in melanoma and anti-PD-1/anti-PD-L1 therapies were mainly adopted in other tumor types in HER2-mutated patients (Table S3). This evidence concerns the gene CTLA4 and neoplasm.